1. Haass C, Selkoe DJ: Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell 1993, 75(6):1039-1042.
2. Glenner GG, Wong CW: Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984, 120(3):885-890.
3. Selkoe DJ, Hardy J: The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 2016, 8(6):595-608.
4. Fandos N, Perez-Grijalba V, Pesini P, Olmos S, Bossa M, Villemagne VL, Doecke J, Fowler C, Masters CL, Sarasa M et al: Plasma amyloid beta 42/40 ratios as biomarkers for amyloid beta cerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst) 2017, 8:179-187.
5. Giudici KV, de Souto Barreto P, Guyonnet S, Li Y, Bateman RJ, Vellas B, Group MD: Assessment of Plasma Amyloid-beta42/40 and Cognitive Decline Among Community-Dwelling Older Adults. JAMA Netw Open 2020, 3(12):e2028634.
6. Perez-Grijalba V, Romero J, Pesini P, Sarasa L, Monleon I, San-Jose I, Arbizu J, Martinez-Lage P, Munuera J, Ruiz A et al: Plasma Abeta42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study. J Prev Alzheimers Dis 2019, 6(1):34-41.
7. Wang H, Kulas JA, Wang C, Holtzman DM, Ferris HA, Hansen SB: Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol. Proceedings of the National Academy of Sciences 2021, 118(33):e2102191118.
8. Deane R, Bell RD, Sagare A, Zlokovic BV: Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 2009, 8(1):16-30.
9. Lemere CA, Spooner ET, LaFrancois J, Malester B, Mori C, Leverone JF, Matsuoka Y, Taylor JW, DeMattos RB, Holtzman DM et al: Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis 2003, 14(1):10-18.
10. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J et al: Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000, 106(12):1489-1499.
11. Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ, Wagner SL, Troncoso JC, Kawas CH, Katzman R et al: Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest 2000, 106(9):1159-1166.
12. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Betsholtz C, Armulik A, Sallstrom J et al: Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012, 485(7399):512-516.
13. Rawat V, Wang S, Sima J, Bar R, Liraz O, Gundimeda U, Parekh T, Chan J, Johansson JO, Tang C et al: ApoE4 Alters ABCA1 Membrane Trafficking in Astrocytes. J Neurosci 2019, 39(48):9611-9622.
14. Boehm-Cagan A, Bar R, Liraz O, Bielicki JK, Johansson JO, Michaelson DM: ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies. J Alzheimers Dis 2016, 54(3):1219-1233.
15. Hafiane A, Bielicki JK, Johansson JO, Genest J: Novel Apo E-Derived ABCA1 Agonist Peptide (CS-6253) Promotes Reverse Cholesterol Transport and Induces Formation of prebeta-1 HDL In Vitro. PLoS One 2015, 10(7):e0131997.
16. Boehm-Cagan A, Bar R, Harats D, Shaish A, Levkovitz H, Bielicki JK, Johansson JO, Michaelson DM: Differential Effects of apoE4 and Activation of ABCA1 on Brain and Plasma Lipoproteins. PLoS One 2016, 11(11):e0166195.
17. Sjödin S, Brinkmalm G, Öhrfelt A, Parnetti L, Paciotti S, Hansson O, Hardy J, Blennow K, Zetterberg H, Brinkmalm A: Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease. Alzheimers Res Ther 2019, 11(1):82.
18. Toth CA, Kuklenyik Z, Jones JI, Parks BA, Gardner MS, Schieltz DM, Rees JC, Andrews ML, McWilliams LG, Pirkle JL et al: On-column trypsin digestion coupled with LC-MS/MS for quantification of apolipoproteins. Journal of Proteomics 2017, 150:258-267.
19. Gardner MS, Kuklenyik Z, Lehtikoski A, Carter KA, McWilliams LG, Kusovschi J, Bierbaum K, Jones JI, Rees J, Reis G et al: Development and application of a high throughput one-pot extraction protocol for quantitative LC-MS/MS analysis of phospholipids in serum and lipoprotein fractions in normolipidemic and dyslipidemic subjects. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 2019, 1118-1119:137-147.
20. Gardner MS, McWilliams LG, Jones JI, Kuklenyik Z, Pirkle JL, Barr JR: Simultaneous Quantification of Free Cholesterol, Cholesteryl Esters, and Triglycerides without Ester Hydrolysis by UHPLC Separation and In-Source Collision Induced Dissociation Coupled MS/MS. Journal of The American Society for Mass Spectrometry 2017.
21. Kuklenyik Z, Jones JI, Gardner MS, Schieltz DM, Parks BA, Toth CA, Rees JC, Andrews ML, Carter K, Lehtikoski AK et al: Core lipid, surface lipid and apolipoprotein composition analysis of lipoprotein particles as a function of particle size in one workflow integrating asymmetric flow field-flow fractionation and liquid chromatography-tandem mass spectrometry. PLOS ONE 2018, 13(4):e0194797.
22. Bales KR, Liu F, Wu S, Lin S, Koger D, DeLong C, Hansen JC, Sullivan PM, Paul SM: Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J Neurosci 2009, 29(21):6771-6779.
23. Martinez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, Diamandis EP, Nielsen HM: Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls. Acta Neuropathol 2014, 127(5):633-643.
24. Rasmussen KL, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R: Plasma levels of apolipoprotein E and risk of dementia in the general population. Ann Neurol 2015, 77(2):301-311.
25. Rasmussen KL, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R: Plasma apolipoprotein E levels and risk of dementia: A Mendelian randomization study of 106,562 individuals. Alzheimers Dement 2018, 14(1):71-80.
26. Wolters FJ, Koudstaal PJ, Hofman A, van Duijn CM, Ikram MA: Serum apolipoprotein E is associated with long-term risk of Alzheimer's disease: The Rotterdam Study. Neurosci Lett 2016, 617:139-142.
27. Xia M, Hou M, Zhu H, Ma J, Tang Z, Wang Q, Li Y, Chi D, Yu X, Zhao T et al: Anthocyanins induce cholesterol efflux from mouse peritoneal macrophages: the role of the peroxisome proliferator-activated receptor {gamma}-liver X receptor {alpha}-ABCA1 pathway. J Biol Chem 2005, 280(44):36792-36801.
28. Panza F, D'Introno A, Colacicco AM, Capurso C, Pichichero G, Capurso SA, Capurso A, Solfrizzi V: Lipid metabolism in cognitive decline and dementia. Brain Res Rev 2006, 51(2):275-292.
29. Poirier J: Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol Med 2003, 9(3):94-101.
30. Yassine HN, Finch CE: APOE Alleles and Diet in Brain Aging and Alzheimer's Disease. Front Aging Neurosci 2020, 12:150.
31. Poduri A, Gearing M, Rebeck GW, Mirra SS, Tigges J, Hyman BT: Apolipoprotein E4 and beta amyloid in senile plaques and cerebral blood vessels of aged rhesus monkeys. Am J Pathol 1994, 144(6):1183-1187.
32. Hutchins PM, Ronsein GE, Monette JS, Pamir N, Wimberger J, He Y, Anantharamaiah GM, Kim DS, Ranchalis JE, Jarvik GP et al: Quantification of HDL particle concentration by calibrated ion mobility analysis. Clin Chem 2014, 60(11):1393-1401.
33. Rye KA, Barter PJ: Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2004, 24(3):421-428.
34. Mackey RH, Greenland P, Goff DC, Jr., Lloyd-Jones D, Sibley CT, Mora S: High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol 2012, 60(6):508-516.
35. Wahl PW, Warnick GR, Albers JJ, Hoover JJ, Walden CE, Bergelin RO, Ogilvie JT, Hazzard WR, Knopp RH: Distribution of lipoproteins triglyceride and lipoprotein cholesterol in an adult population by age, sex, and hormone use- The Pacific Northwest Bell Telephone Company health survey. Atherosclerosis 1981, 39(1):111-124.
36. LaDu MJ, Munson GW, Jungbauer L, Getz GS, Reardon CA, Tai LM, Yu C: Preferential interactions between ApoE-containing lipoproteins and Abeta revealed by a detection method that combines size exclusion chromatography with non-reducing gel-shift. Biochim Biophys Acta 2012, 1821(2):295-302.
37. Jack CR, Jr., Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ: Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9(1):119-128.
38. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P et al: Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013, 12(4):357-367.
39. Van Valkenburgh J, Meuret C, Martinez AE, Kodancha V, Solomon V, Chen K, Yassine HN: Understanding the Exchange of Systemic HDL Particles Into the Brain and Vascular Cells Has Diagnostic and Therapeutic Implications for Neurodegenerative Diseases. Frontiers in physiology 2021, 12:700847-700847.
40. Matsubara E, Sekijima Y, Tokuda T, Urakami K, Amari M, Shizuka-Ikeda M, Tomidokoro Y, Ikeda M, Kawarabayashi T, Harigaya Y et al: Soluble Abeta homeostasis in AD and DS: impairment of anti-amyloidogenic protection by lipoproteins. Neurobiol Aging 2004, 25(7):833-841.
41. Tamaki C, Ohtsuki S, Iwatsubo T, Hashimoto T, Yamada K, Yabuki C, Terasaki T: Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver. Pharm Res 2006, 23(7):1407-1416.
42. Shelburne F, Hanks J, Meyers W, Quarfordt S: Effect of apoproteins on hepatic uptake of triglyceride emulsions in the rat. J Clin Invest 1980, 65(3):652-658.
43. Yamada N, Murase T: Modulation, by apolipoprotein E, of lipoprotein lipase activity. Biochem Biophys Res Commun 1980, 94(2):710-715.
44. Oram JF, Vaughan AM: ATP-Binding cassette cholesterol transporters and cardiovascular disease. Circ Res 2006, 99(10):1031-1043.
45. Kingwell BA, Chapman MJ, Kontush A, Miller NE: HDL-targeted therapies: progress, failures and future. Nat Rev Drug Discov 2014, 13(6):445-464.
46. Vitali C, Wellington CL, Calabresi L: HDL and cholesterol handling in the brain. Cardiovasc Res 2014, 103(3):405-413.
47. Harr SD, Uint L, Hollister R, Hyman BT, Mendez AJ: Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease. J Neurochem 1996, 66(6):2429-2435.
48. Robert J, Stukas S, Button E, Cheng WH, Lee M, Fan J, Wilkinson A, Kulic I, Wright SD, Wellington CL: Reconstituted high-density lipoproteins acutely reduce soluble brain Abeta levels in symptomatic APP/PS1 mice. Biochim Biophys Acta 2016, 1862(5):1027-1036.
49. Kawano M, Kawakami M, Otsuka M, Yashima H, Yaginuma T, Ueki A: Marked decrease of plasma apolipoprotein AI and AII in Japanese patients with late-onset non-familial Alzheimer's disease. Clin Chim Acta 1995, 239(2):209-211.
50. Liu HC, Hu CJ, Chang JG, Sung SM, Lee LS, Yuan RY, Leu SJ: Proteomic identification of lower apolipoprotein A-I in Alzheimer's disease. Dement Geriatr Cogn Disord 2006, 21(3):155-161.
51. Merched A, Xia Y, Visvikis S, Serot JM, Siest G: Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol Aging 2000, 21(1):27-30.
52. Gupta VB, Wilson AC, Burnham S, Hone E, Pedrini S, Laws SM, Lim WL, Rembach A, Rainey-Smith S, Ames D et al: Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort. Alzheimers Res Ther 2015, 7(1):16.
53. Koldamova RP, Lefterov IM, Lefterova MI, Lazo JS: Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. Biochemistry 2001, 40(12):3553-3560.
54. Paula-Lima AC, Tricerri MA, Brito-Moreira J, Bomfim TR, Oliveira FF, Magdesian MH, Grinberg LT, Panizzutti R, Ferreira ST: Human apolipoprotein A-I binds amyloid-beta and prevents Abeta-induced neurotoxicity. Int J Biochem Cell Biol 2009, 41(6):1361-1370.
55. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, Marky A, Lenting PJ, Wu Z, Zarcone T et al: Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 2007, 13(9):1029-1031.
56. Rosenson RS, Brewer HB, Jr., Ansell BJ, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR: Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol 2016, 13(1):48-60.
57. Rhee EJ, Byrne CD, Sung KC: The HDL cholesterol/apolipoprotein A-I ratio: an indicator of cardiovascular disease. Current opinion in endocrinology, diabetes, and obesity 2017, 24(2):148-153.
58. Fujiyoshi M, Ohtsuki S, Hori S, Tachikawa M, Terasaki T: 24S-hydroxycholesterol induces cholesterol release from choroid plexus epithelial cells in an apical- and apoE isoform-dependent manner concomitantly with the induction of ABCA1 and ABCG1 expression. J Neurochem 2007, 100(4):968-978.
59. Cavelier C, Lorenzi I, Rohrer L, von Eckardstein A: Lipid efflux by the ATP-binding cassette transporters ABCA1 and ABCG1. Biochim Biophys Acta 2006, 1761(7):655-666.
60. Young EK, Chatterjee C, Sparks DL: HDL-ApoE content regulates the displacement of hepatic lipase from cell surface proteoglycans. Am J Pathol 2009, 175(1):448-457.
61. Connelly PW: The role of hepatic lipase in lipoprotein metabolism. Clin Chim Acta 1999, 286(1-2):243-255.
62. Robert J, Button EB, Yuen B, Gilmour M, Kang K, Bahrabadi A, Stukas S, Zhao W, Kulic I, Wellington CL: Clearance of beta-amyloid is facilitated by apolipoprotein E and circulating high-density lipoproteins in bioengineered human vessels. Elife 2017, 6.